# EU Panel Recommends Wegovy for Cardiovascular Risk Reduction – Novo Nordisk has received a positive opinion from the European Medicines Agency for expanding the use of Wegovy to include cardiovascular risk reduction. – Wegovy (semaglutide 2.4 mg) has already been approved for chronic weight management in adults. – This positive recommendation is based on results from the SELECT cardiovascular outcomes trial, which demonstrated significant risk reduction in adults with overweight or obesity and prior cardiovascular disease. – The expanded indication will provide healthcare professionals with a new option for managing both weight and cardiovascular risk in eligible patients. ### Positive Recommendation for Wegovy’s Cardiovascular Benefits Novo Nordisk’s success in obtaining a favorable opinion from the EU panel for Wegovy’s expanded use underscores the potential impact this medication can have on not only weight management but also cardiovascular risk reduction. By leveraging the proven efficacy of semaglutide 2.4 mg in addressing both obesity and cardiovascular disease, healthcare providers can offer a comprehensive treatment approach to patients seeking to improve their overall health. This milestone represents a significant step forward in the fight against obesity and its associated comorbidities, highlighting the importance of innovative pharmaceutical solutions in promoting wellness. For individuals considering weight management or cardiovascular risk reduction options, exploring the benefits of Wegovy under the guidance of healthcare professionals can lead to positive outcomes in their health journey. Weight Loss Disclaimer: Individual results may vary. Exercise and proper diet are necessary to achieve and maintain weight loss. Consult with a healthcare provider before starting any weight loss program. Contact Mindful Evolution at https://yourmindfulevolution.com or call/text us at 954-639-9960 to learn more about telehealth services available in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.